70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

Compounded semaglutide and Ozempic are different products. While both may be used in people with type 2 diabetes, Ozempic is approved by the FDA, but compounded semaglutide is not. Compounded ...

"We are deeply disappointed that the (court) misapprehended or failed to take into consideration the clear and convincing evidence that demonstrates that the manufactured supply of semaglutide is ...

Semaglutide is an injectable medication available as Ozempic and Rybelsus to treat type 2 diabetes and Wegovy for managing overweight or obesity. GLP-1 is a hormone produced by the intestines ...

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug ...

Semaglutide medications like Ozempic and Wegovy have exploded in popularity in recent years due to their effectiveness in diabetes control and weight loss. Research has revealed additional ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Researchers estimated that nearly 25,000 ED visits were related to semaglutide adverse events. They were surprised to learn that 16% involved hypoglycemia. An estimated 24,499 people visited the ...

Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...